CD109 促进胰腺导管腺癌细胞的致瘤能力和转移运动能力。
CD109 promotes the tumorigenic ability and metastatic motility of pancreatic ductal adenocarcinoma cells.
机构信息
Division of Molecular and Cellular Oncology, Miyagi Cancer Center Research Institute, Natori, 9811293, Japan; Department of Surgery, Tohoku University Graduate School of Medicine, Sendai, 9808575, Japan.
Division of Molecular and Cellular Oncology, Miyagi Cancer Center Research Institute, Natori, 9811293, Japan; Department of Cancer Science, Tohoku University Graduate School of Medicine, Sendai, 9808575, Japan.
出版信息
Pancreatology. 2020 Apr;20(3):493-500. doi: 10.1016/j.pan.2020.01.013. Epub 2020 Jan 22.
BACKGROUND
Accumulating evidence indicates that CD109, a glycosylphosphatidylinositol-anchored glycoprotein, is highly expressed in human epithelial carcinomas of multiple organs including the pancreas, but its functional role in carcinoma development has not yet been fully clarified. The aim of this study was to investigate the role of CD109 in the malignancy of pancreatic ductal adenocarcinoma (PDAC).
METHODS
PDAC specimens of 145 cases were immunostained for CD109, and correlations between CD109 expression and clinicopathological conditions were analyzed. CD109 expression in PANC-1 cells, a PDAC-derived cell line, was decreased by siRNA or shRNA and its effect on the malignancy of PANC-1 cells was examined.
RESULTS
Suppression of CD109 expression in PANC-1 cells resulted in reduction of in vitro cell motility and tumorigenicity in xenografts. Based on these results, we investigated the relationship between CD109 expression and metastasis of PDAC using tumor tissue specimens. Among 106 recurrent cases of 145 PDAC, there was a tendency for CD109-positive cases to be accompanied by distant metastasis.
CONCLUSIONS
CD109 plays a critical role in the promotion of tumorigenic ability and cellular motility relating to metastasis of PDAC cells.
背景
越来越多的证据表明，CD109 是一种糖基磷脂酰肌醇锚定糖蛋白，在包括胰腺在内的多个器官的人类上皮癌中高度表达，但它在癌发生发展中的功能作用尚未完全阐明。本研究旨在探讨 CD109 在胰腺导管腺癌（PDAC）恶性程度中的作用。
方法
对 145 例 PDAC 标本进行 CD109 免疫染色，并分析 CD109 表达与临床病理条件之间的相关性。通过 siRNA 或 shRNA 降低 PDAC 衍生细胞系 PANC-1 细胞中的 CD109 表达，并检测其对 PANC-1 细胞恶性程度的影响。
结果
抑制 PANC-1 细胞中的 CD109 表达导致体外细胞迁移和异种移植肿瘤生成能力降低。基于这些结果，我们使用肿瘤组织标本研究了 CD109 表达与 PDAC 转移之间的关系。在 145 例 PDAC 中的 106 例复发病例中，CD109 阳性病例有伴随远处转移的趋势。
结论
CD109 在促进 PDAC 细胞的致瘤能力和与转移相关的细胞迁移中起关键作用。
Zotero 插件